Saloojas, Inc. v. United States Department of Health and Human Services, et al.

CourtDistrict Court, N.D. California
DecidedFebruary 12, 2026
Docket3:25-cv-04735
StatusUnknown

This text of Saloojas, Inc. v. United States Department of Health and Human Services, et al. (Saloojas, Inc. v. United States Department of Health and Human Services, et al.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Saloojas, Inc. v. United States Department of Health and Human Services, et al., (N.D. Cal. 2026).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 SALOOJAS, INC., Case No. 25-cv-04735-EMC

8 Plaintiff, ORDER GRANTING MOTION TO 9 v. DISMISS

10 UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, et Docket No. 10 11 al.,

12 Defendants.

13 14 I. INTRODUCTION 15 Defendants move to dismiss Saloojas, Inc.’s (“Saloojas”) Complaint, which seeks to 16 compel the United States Department of Health and Human Services (“HHS”), Department of 17 Labor, and Department of the Treasury (“Treasury”), along with their respective Secretaries, to 18 enforce the reimbursement provisions of two statutes passed during the COVID-19 pandemic: the 19 Families First Coronavirus Act (“FFCRA”) and the Coronavirus Aid, Relief, and Economic 20 Security Act (“CARES Act”). Saloojas alleges that it is owed more than $18 million for tens of 21 thousands of COVID-19 diagnostic tests that it provided to the public and contends that the federal 22 agencies have unlawfully withheld or unreasonably delayed enforcement action under the 23 Administrative Procedure Act (“APA”), 5 U.S.C. § 706(1). Saloojas asserts a claim under the 24 Mandamus Act in the alternative, as well as a Fifth Amendment takings claim. 25 The Court holds that Saloojas’s claims are not reviewable because enforcement decisions 26 are committed to agency discretion. Accordingly, the Court GRANTS the motion to dismiss. 27 1 II. BACKGROUND 2 A. Statutory Framework 3 In 2020, as part of the federal government’s response to the COVID-19 pandemic, 4 Congress enacted FFCRA. Pub. L. No. 116-127, 134 Stat. 178. Section 6001 of FFCRA, titled 5 “Coverage of Testing for COVID-19,” requires group health plans and health insurance providers 6 to cover the cost of COVID-19 diagnostic testing at no additional expense to insureds. Id. § 7 6001(a). Section 6001 also contains an enforcement provision, stating that the provisions of 8 subsection (a) “shall be applied by the Secretary of Health and Human Services, Secretary of 9 Labor, and Secretary of the Treasury” to insurers “as if included in” certain provisions of the 10 Public Health Service Act (“PHSA”), the Employee Retirement Income Security Act of 1974 11 (“ERISA”), and the Internal Revenue Code of 1986 (“IRC”). Id. § 6001(b). The FFCRA further 12 provides that the Secretaries of these respective agencies “may implement the provisions of this 13 section through sub-regulatory guidance, program instruction or otherwise.” Id. § 6001(c). 14 The relevant FFCRA provisions state:

15 (b) ENFORCEMENT. — The provisions of subsection (a) [mandating insurers to cover costs of COVID-19 diagnostic testing] 16 shall be applied by the Secretary of Health and Human Services, Secretary of Labor, and Secretary of the Treasury to group health 17 plans and health insurance issuers offering group or individual health insurance coverage as if included in the provisions of part A 18 of title XXVII of the Public Health Service ACT, part 7 of the Employee Retirement Income Security ACT of 1974, and 19 subchapter B of chapter 100 of the Internal Revenue Code of 1986, as applicable. 20 (c) IMPLEMENTATION. — The Secretary of Health and Human 21 Services, Secretary of Labor, and Secretary of the Treasury may implement the provisions of this section through sub-regulatory 22 guidance, program instruction or otherwise. 23 Pub. L. No. 116-127, 134 Stat. 178 § 6001(b)–(c) (emphases added). 24 Later in 2020, Congress enacted the CARES Act. Pub. L. No. 116-136, 134 Stat. 281. 25 Section 3202 of the CARES Act addresses the pricing of COVID-19 diagnostic testing. It 26 provides that group health plans or insurers covering COVID-19 diagnostic testing “shall 27 reimburse the provider of the [COVID-19] diagnostic testing” at either (1) a negotiated rate that 1 that equals the cash price for such service as listed by the provider on a public internet website,” 2 unless the plan or issuer negotiates a lower rate. Id. § 3202(a). Section 3202 also imposes 3 obligations on providers to list the cash price for any COVID-19 diagnostic testing on a public 4 internet website. Id. § 3202(b)(1). The statute authorizes the Secretary of Health and Human 5 Services to impose civil monetary penalties on providers that fail to comply with this price posting 6 requirement. Id. § 3202(b)(2). 7 The relevant CARES Act provisions state:

8 PRICING OF DIAGNOSTIC TESTING. (a) REIMBURSEMENT RATES. — A group health plan or a health 9 insurance issuer providing coverage of items and services described in section 6001(a) of [the FFCRA] with respect to an 10 enrollee shall reimburse the provider of the diagnostic testing as follows: 11 . . . 12 (2) If the health plan or issuer does not have a negotiated rate 13 with such provider, such plan or issuer shall reimburse the provider in an amount that equals the cash price for such 14 service as listed by the provider on a public internet website.

15 (b) REQUIREMENT TO PUBLICIZE CASH PRICE FOR DIAGNOSTIC TESTING FOR COVID-19. — 16 (1) IN GENERAL. — During the emergency period . . . each 17 provider of a diagnostic test for COVID-19 shall make public the cash price for such test on a public internet 18 website of such provider.

19 (2) CIVIL MONETARY PENALTIES. — The Secretary of Health and Human Services may impose a civil monetary 20 penalty on any provider of a diagnostic test for COVID- 19 that is not in compliance with paragraph (1) and has not 21 completed a corrective action plan to comply with the requirements of such paragraph, in an amount not to 22 exceed $300 per day that the violation is ongoing. 23 Pub. L. No. 116-136, 134 Stat. 281 § 3202. 24 Following enactment of the FFCRA and CARES Act, HHS, the Department of Labor, and 25 Treasury issued joint guidance, including a series of frequently asked questions, describing how 26 the statutes would be implemented and enforced. The guidance stated that the Departments would 27 enforce the applicable provisions of the FFCRA and CARES Act “in conjunction with states, 1 FAQs About Families First Coronavirus Response ACT and Coronavirus Aid, Relief, and 2 Economic Security ACT Implementation Part 43 (June 23, 2020). The joint FAQs are silent about 3 any mandatory obligation for Secretaries to investigate or enforce alleged non-payments. The 4 only reference to enforcement mechanisms states that the CARES Act “grants the Secretary of 5 HHS authority to impose civil monetary penalties on any provider of a diagnostic test for COVID- 6 19 that does not comply with the requirement to publicly post the cash price for the COVID-19 7 diagnostic test on the provider’s website . . . .” 8 The FFCRA and CARES Act direct the Secretaries of HHS, Department of Labor, and 9 Treasury to apply the statutory provisions “as if included in the provisions” of the PHSA, ERISA, 10 and IRC. Once § 6001 is incorporated into the PHSA, ERISA, and IRC, enforcement may 11 proceed under the mechanisms established by those statutes. Understanding the legislative 12 scheme is thus critical to assessing whether Saloojas has identified a legally required agency 13 action. 14 1. Public Health Service Act (PHSA) 15 FFCRA § 6001 directs the HHS Secretary to incorporate its provisions “as if included” in 16 Part A of title XXVII of the PHSA. Part A of title XXVII of the PHSA is codified at 42 U.S.C. § 17 300gg through 300gg-28. Section 300gg-22 is the PHSA’s enforcement provision, laying out the 18 Secretary’s enforcement powers and the division of enforcement authority between HHS and the 19 states.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pennsylvania Coal Co. v. Mahon
260 U.S. 393 (Supreme Court, 1922)
Heckler v. Chaney
470 U.S. 821 (Supreme Court, 1985)
Norton v. Southern Utah Wilderness Alliance
542 U.S. 55 (Supreme Court, 2004)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Fallini v. Hodel
783 F.2d 1343 (Ninth Circuit, 1986)
Maya v. Centex Corp.
658 F.3d 1060 (Ninth Circuit, 2011)
Noe D. Lujan v. Robert J. Tansy
2 F.3d 1031 (Tenth Circuit, 1993)
Maynard Alves v. United States
133 F.3d 1454 (Federal Circuit, 1998)
Manzarek v. St. Paul Fire & Marine Insurance
519 F.3d 1025 (Ninth Circuit, 2008)
Mendiondo v. Centinela Hospital Medical Center
521 F.3d 1097 (Ninth Circuit, 2008)
Paulsen v. CNF INC.
559 F.3d 1061 (Ninth Circuit, 2009)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Valles v. Pima County
776 F. Supp. 2d 995 (D. Arizona, 2011)
United States v. Barlow
732 F. Supp. 2d 1 (E.D. New York, 2010)
Nozzi v. Housing Authority
806 F.3d 1178 (Ninth Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Saloojas, Inc. v. United States Department of Health and Human Services, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/saloojas-inc-v-united-states-department-of-health-and-human-services-et-cand-2026.